FePt nanoparticles: a novel nanoprobe for enhanced HeLa cells sensitivity to chemoradiotherapy
FePt nanoparticles: a novel nanoprobe for enhanced HeLa cells sensitivity to chemoradiotherapy
复制标题
FePt 纳米粒子：一种新型纳米探针，可增强 HeLa 细胞对放化疗的敏感性
DOI：
10.1039/c6ra03990a
复制
发表时间：
2016-01-01
期刊：
影响因子：
3.9
通讯作者：
Jiang, Changzhong
中科院分区：
文献类型：
--
作者：
Bao, Zhirong;He, Mingyang;Jiang, Changzhong
与单纯化疗或放疗相比，放化疗是肿瘤学中一种成熟的治疗模式，可持续改善局部肿瘤控制。尽管其重要性，很少有药物已被确定，以进一步提高治疗率和减少并发症的发生率。纳米医学的进步为改善放化疗提供了创新策略。在本研究中，我们使用HeLa细胞和HEK 293 T细胞评估FePt纳米颗粒（NPs）在放化疗中的有效性和安全性。合成了不同组成（x = 26、53和77）的FexPt 100 −x纳米颗粒，并通过X射线衍射、透射电子显微镜和傅里叶变换红外光谱进行了表征。在配体交换后，通过MTT测定法在HEK 293 T细胞中评价了FexPt 100 −x NPs的细胞毒性，同时在体外HeLa细胞中研究了FePt NPs对细胞毒性的组成影响以及FePt NPs与临床相关MV能量的X射线辐射组合的潜在应用。此外，通过原子吸收光谱法和透射电子显微镜间接测量细胞对NPs的摄取。结果表明，FexPt 100 −x NPs在孵育24小时后以浓度和组成依赖性方式抑制HeLa细胞的生长，在给定浓度（0-20 μg mL−1）下对HEK 293 T细胞的细胞毒性较低。此外，与单独FePt NPs处理组或单独放射组相比，FePt NPs和放射治疗的组合导致HeLa细胞的显著抑制。此外，Fe 53 Pt 47 NPs对HeLa细胞表现出显著的细胞毒性和增强的放射增敏作用，而不损伤HEK 293 T细胞，理论上可能满足个性化放化疗的最终目标。我们目前的工作表现出高疗效的FePt纳米粒子与放射治疗相结合，没有明显的细胞毒性，这表明FePt纳米粒子作为一个有前途的纳米探针在改善肿瘤放化疗的结果的潜力。
Chemoradiotherapy is a well-established treatment paradigm in oncology to consistently improve local tumor control compared to the sole administration of chemotherapy or radiotherapy. Despite its importance, few agents have been identified to further improve the therapeutic ratio and reduce the incidence of complications. Advances in nanomedicine have offered innovative strategies to improve chemoradiotherapy. In the present study, we evaluated the efficacy and safety of FePt nanoparticles (NPs) in chemoradiotherapy using HeLa cells and HEK293T cells. FexPt100−x NPs at different compositions (x = 26, 53 and 77) were synthesized and characterized by means of X-ray diffraction, transmission electron microscopy, and Fourier transform infrared spectroscopy. After ligand exchange, the cytotoxicity of FexPt100−x NPs was evaluated by MTT assay in HEK293T cells while the composition effects of FePt NPs on the cytotoxicity and the potential application of FePt NPs in combination with X-ray radiation at clinically relevant MV energies were investigated in HeLa cells in vitro. Besides, the cellular uptake of NPs was measured indirectly by atomic absorption spectroscopy and transmission electron microscopy. The results indicated that FexPt100−x NPs inhibited the growth of HeLa cells in a concentration- and composition-dependent manner after 24 h incubation, with low cytotoxicity to HEK293T cells at the given concentrations (0–20 μg mL−1). Furthermore, the combination of FePt NPs and radiotherapy resulted in a marked inhibition of HeLa cells, in contrast with that of the individual FePt NPs treated group or the radiation alone group. Moreover, Fe53Pt47 NPs, exhibiting significant cytotoxicity and enhanced radiosensitization effects on HeLa cells without damage to HEK293T cells, might theoretically satisfy the ultimate goal of personalized chemoradiotherapy. Our present work exhibited high therapeutic efficacy of FePt NPs in combination with radiotherapy without apparent cytotoxicity, suggesting the potential of FePt NPs as a promising nanoprobe in improving the outcome of tumor chemoradiotherapy.